# Yinuokang (Nanjing) Biomedical Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/yinuokang-nanjing-biomedical-co

- Industry: Pharmaceuticals
- Headquarters: Nanjing, China
- Total disclosed funding: $15M
- Latest round: Angel (May 13, 2022)
- Investors on record: 4

## About

Established in 2021 and based in Nanjing, China, Yinuokang (Nanjing) Biomedical Co., Ltd. operates as an anticancer drug developer that focuses on targeted protein degradation field. The founder of this company, Dr. Xavilin, has over 25 years of drug discovery experience, including co-inventing the sensational heavyweight drug celecoxib. In December 2023, Yinuokang (Nanjing) Biomedical Co., Ltd. raised approximately CNY 100 million in pre-series A funding led by new investor Golden China Fund.
 
The company provides anticancer drugs. The company provides focuses on targeted protein degradation drugs and tumour immune drugs R&D. In addition, it also provides pharmaceutical commissioning and drug clinical trial services.


The company plans to conduct two IND-enabling phases with "first-in-class" potential in 2024, with the first IND application expected to be formally filed in 2024.

## Funding rounds

- Angel, May 13, 2022, $15M — Harmony Venture, Ming Bioventures, Cheng Yi Capital, JITRI

## Investors

- Harmony Venture (https://capitalatlas.ai/funds/harmony-venture) — Angel
- Ming Bioventures (https://capitalatlas.ai/funds/ming-bioventures) — Angel
- Cheng Yi Capital (https://capitalatlas.ai/funds/cheng-yi-capital) — Angel
- JITRI — Angel